Sanofi, GlaxoSmithKline Get India's Approval For Late-Stage Vaccine Trial
Sanofi SA and GlaxoSmithKline Plc have received an approval from Indian authorities for a late-stage clinical trial of their protein-based COVID-19 vaccine candidate, the drugmakers said on Thursday.
No comments:
Post a Comment